Prosecution Insights
Last updated: October 04, 2026
Application No. 17/997,340

METHOD FOR PRODUCING EXTRACELLULAR VESICLES FROM THREE-DIMENSIONALLY CULTURED STEM CELLS

Non-Final OA §112
Filed
Oct 27, 2022
Priority
Apr 28, 2020 — RE 10-2020-0051640 +1 more
Examiner
LIU, TRACY
Art Unit
1614
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Konkuk University Industrial Cooperation Corp.
OA Round
5 (Non-Final)
54%
Grant Probability
Moderate
5-6
OA Rounds
0m
Est. Remaining
82%
With Interview

Examiner Intelligence

Grants 54% of resolved cases
54%
Career Allowance Rate
372 granted / 683 resolved
-5.5% vs TC avg
Strong +27% interview lift
Without
With
+27.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
88 currently pending
Career history
779
Total Applications
across all art units

Statute-Specific Performance

§101
1.2%
-38.8% vs TC avg
§103
48.9%
+8.9% vs TC avg
§102
4.4%
-35.6% vs TC avg
§112
24.5%
-15.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 683 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims included in the prosecution are claims 1, 2, 10, 11 and 14-18. Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 06/23/2026 has been entered. Applicants' arguments, filed 06/23/2026, have been fully considered. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1, 2, 10, 11 and 14-18 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. This is a new matter rejection. Claim 1 recites at least 10 ng/mL TGF-β3. The claim fails to comply with the written description requirement since the phrase “at least” has no upper limit and the specification does not appear to have support for all amounts of TGF-β3 greater than 10 ng/mL. At best, the specification appears to only have support for 10 ng/mL as shown in Fig. 2. Conclusion Claims 1, 2, 10, 11 and 14-18 are rejected. No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to TRACY LIU whose telephone number is (571)270-5115. The examiner can normally be reached Mon-Fri 9 am - 5 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Ali Soroush can be reached at 571-272-9925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /TRACY LIU/Primary Examiner, Art Unit 1614
Read full office action

Prosecution Timeline

Show 7 earlier events
Mar 12, 2026
Response Filed
Mar 12, 2026
Response after Non-Final Action
Mar 31, 2026
Final Rejection mailed — §112
Jun 16, 2026
Examiner Interview Summary
Jun 16, 2026
Applicant Interview (Telephonic)
Jun 23, 2026
Request for Continued Examination
Jun 24, 2026
Response after Non-Final Action
Aug 05, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12714656
AQUEOUS ORAL CARE IODIDE-CONTAINING COMPOSITIONS, METHODS, AND KITS
2y 11m to grant Granted Aug 25, 2026
Patent 12636246
PROCESS FOR COLOURING HAIR KERATIN FIBERS, COMPRISING THE APPLICATION OF A COMPOSITION COMPRISING AT LEAST ONE (POLY)CARBODIIMIDE COMPOUND AND A COMPOSITION COMPRISING AT LEAST ONE ASSOCIATIVE POLYMER AND A PARTICULAR COMPOUND
2y 8m to grant Granted May 26, 2026
Patent 12605314
BROAD-SPECTRUM, MINERAL, PHOTOPROTECTIVE COMPOSITIONS
2y 9m to grant Granted Apr 21, 2026
Patent 12527886
RADIOPHARMACEUTICALS AND COMPOSITION FOR THROMBUS IMAGING
3y 3m to grant Granted Jan 20, 2026
Patent 12514799
CHEMICAL MEMBRANE COMPLEX REPAIR SOLUTION AND METHOD OF USING THE SAME
7y 5m to grant Granted Jan 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

5-6
Expected OA Rounds
54%
Grant Probability
82%
With Interview (+27.3%)
3y 2m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 683 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month